Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.
about
Parkinson's disease gene therapy: success by design meets failure by efficacyGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryCurrent prospects and challenges for epilepsy gene therapyThe glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitabilityCurrent prospects for RNA interference-based therapiesElectroacoustic stimulation: now and into the futureCerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees.Targeting neurons of rat nucleus tractus solitarii with the gene transfer vector adeno-associated virus type 2 to up-regulate neuronal nitric oxide synthase.Distinct transduction profiles in the CNS via three injection routes of AAV9 and the application to generation of a neurodegenerative mouse model.Gene therapy for the nervous system: challenges and new strategies.Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.The AAV vector toolkit: poised at the clinical crossroadsClinical applications involving CNS gene transfer.Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's diseaseCurrent advances in using neurotrophic factors to treat neurodegenerative disordersFocusing brain therapeutic interventions in space and time for Parkinson's disease.Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.Recent advances in RNA interference therapeutics for CNS diseases.Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease.Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3α,5α-THP and reduces long-term operant ethanol self-administration.Gene therapy for Parkinson's disease: where are we now and where are we going?Genetic therapy for the nervous system.Targeted gene therapy for the treatment of heart failure.Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Small RNA drugs for prion disease: a new frontier.Atoh1 gene therapy in the cochlea for hair cell regeneration.Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference.How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?Challenges for the application of optical stimulation in the cochlea for the study and treatment of hearing loss.Adeno-Associated Virus-Based Gene Therapy for CNS Diseases.Non-human primate models of PD to test novel therapies.
P2860
Q26851325-1D306B2A-1D32-4516-8C86-F2ABD2E24D0FQ26851517-BD932BA7-1F64-4398-909F-AD8D37B8B1B3Q27002627-F97B78D0-7017-45C0-9023-1177F76EBC96Q27023715-03506C82-A2BD-4FB8-B1A5-B7B1D6D67F8BQ28081164-0EF9F5FA-48F3-45B3-AF6E-BD2D56928039Q28235733-C00BB16C-8D6C-414B-A4D9-ACBADA8CB69FQ30367376-485AF9BD-31C7-4C5F-A8F0-E900284DA20FQ30531601-0F9D78C8-F8F6-4825-BF5A-4D8AA4673E41Q33870720-3693045E-19D2-45E1-A416-B1DF488295F8Q34490776-0A65113C-6A6A-46CC-AE19-4C1B11136CD8Q34498957-342AF128-9436-42FC-8ED5-F9B623A7FFD0Q34762396-71AD78EE-26DD-46A7-8755-849EAE6FA3B1Q35113293-F3302AF1-41CA-432B-81F9-5EB7D965F9A4Q35136635-2D96A993-AF73-416D-88D2-EBEA6C7E5DB8Q35184199-D81B6F73-0939-4394-8116-13A165E6E60CQ35340196-C85F3514-DA44-49BC-96AB-C19235122C3DQ35751582-A51107A7-7175-4DF5-A9CB-3A1BF088414BQ35876224-86078C2E-F935-49A5-B3AF-210EE41ACBA3Q35899850-892B8EF7-B2DC-4601-9492-016A2062E1F4Q35932749-13A2911C-1796-4EB8-8B6B-C59BB7AA1334Q36525034-9132C609-756A-44A3-85DC-65662EF79BB6Q36745293-2307AA7F-0624-4365-A8C2-45D55DC95220Q36951265-2AB6CCD8-A0DB-4640-8C0A-79DF7BA3A125Q36983193-0010A3C6-C53E-4BCB-800F-8345EC96BFA7Q37051728-9DC3F84F-83E6-47A4-B869-3386F3F3874CQ37717621-E6B8B18D-0C5C-41C3-B70E-933859147FD1Q37810994-CC493A94-0FEC-4484-A85D-7D37E8E8CC79Q37856565-5322CB07-CFFD-4DEA-9E58-EA18DF9239F1Q37878086-1BBD53AD-FF34-4A75-9783-729750EE5687Q37895283-E06AE9FA-4AED-4EF7-8BC5-88D07157F53DQ38075068-D2B819F8-D018-4B29-AF0A-882174051067Q38091009-06BAFDF7-74A5-4845-B843-8B99FD69EA7FQ38112216-98C5A94C-A663-444A-851B-D8C23077100DQ38121120-5B7C130F-F6FB-4B1F-880E-A4F7ED3783C1Q38342851-8B2F07EE-5195-44C1-8C54-0A5C1F1D8649Q38351487-DEFEEC29-DDCA-4EB6-8DCD-CDC3C3753B42Q38532562-0861FA8E-CFAF-4BEA-AEEC-C74056C08F8DQ38783334-04C81E26-228C-436A-AA9D-A88148753CA2Q38856794-F2CD0E6B-5926-407D-9D19-82353B54502AQ39229450-2F7E1207-2C8F-4E4E-AF80-4101DC59873A
P2860
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@en
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@nl
type
label
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@en
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@nl
prefLabel
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@en
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@nl
P2093
P2860
P356
P1433
P1476
Eight years of clinical improv ...... gene therapy with AAV2-hAADC.
@en
P2093
Jamie L Eberling
John Bringas
John Forsayeth
Krystof S Bankiewicz
Philip Pivirotto
Piotr Hadaczek
P2860
P304
P356
10.1038/MT.2010.106
P577
2010-06-08T00:00:00Z